Why Life Sciences Companies Choose Switzerland to Scale Internationally

As life sciences companies navigate increasingly complex global markets, the decision of where to establish or expand international operations has become a strategic one.

In California, GGBa met with senior executives from biotechnology accelerators, medtech companies, and financial institutions to discuss international scaling strategies and Europe’s evolving innovation landscape.

Across conversations, one theme emerged consistently: companies seeking to expand beyond the United States are not simply looking for geographic presence. They are looking for ecosystems that reduce risk, accelerate execution, and provide long-term stability. In that context, Switzerland is frequently identified as a pragmatic entry point into Europe.

Scaling life sciences: beyond science alone

For biotechnology and medtech companies, scaling is rarely constrained by scientific innovation alone. It is shaped by access to capital, talent availability, regulatory clarity, clinical validation pathways, and long-term business predictability.

Executives emphasized that expansion into Europe remains structurally complex. Unlike the U.S. market, Europe requires multiple market entries, differentiated reimbursement systems, and varied regulatory environments. In this fragmented landscape, choosing the right base becomes critical.

Companies evaluating European expansion therefore prioritize three core elements:

• Access to specialized talent
• Access to growth-stage capital
• Access to infrastructure capable of translating research into clinical and commercial outcomes

Switzerland’s ecosystem aligns with these criteria in several ways.

Bridging the “Valley of Death” in early-stage innovation

One recurring theme in discussions was the challenge of funding early-stage life sciences ventures. While seed capital is often available, the critical growth tranche between initial validation and institutional financing remains difficult to secure.

Switzerland’s public innovation funding mechanisms were cited as an important differentiator. Government-backed programs such as Innosuisse provide substantial early-stage support, helping companies bridge the gap between proof-of-concept and clinical development. Compared to smaller early-stage grant structures elsewhere, this level of backing can meaningfully reduce technical and financial risk at the most vulnerable stage of company development.

For international companies, this signals more than funding availability. It reflects a structural willingness to support innovation before commercial success is fully evident, a factor that strengthens the broader ecosystem.

Talent density and scientific concentration

Access to talent remains a decisive factor in location strategy.

Switzerland’s concentration of life sciences expertise, particularly across Basel, Zurich and Western Switzerland’s “Health Valley”, creates a dense network of researchers, clinicians, and industry professionals. Universities and research institutions consistently produce high-skilled graduates in advanced modalities such as gene and cell therapy, digital health, and precision medicine.

Executives noted that while Switzerland may not always be the lowest-cost location in Europe, the concentration of expertise and experience reduces execution risk. For companies operating in highly regulated and technically complex environments, quality frequently outweighs cost considerations.

In addition, Switzerland’s international workforce and openness to global talent mirror characteristics often associated with leading U.S. innovation hubs, providing cultural and operational familiarity for American firms.

Clinical credibility and adoption pathways

For medtech and clinically oriented companies, hospital partnerships and physician engagement are central to European market entry.

Switzerland’s clinical institutions were repeatedly described as advanced, reputationally strong, and open to piloting innovation. Executives pointed to the ability to work with leading hospitals in Bern, Basel, and Zurich as a way to establish validation that carries credibility beyond national borders.

Switzerland’s regulatory organization, CE-marking alignment, and reimbursement clarity also contribute to smoother product integration. The ability to incorporate new technologies into existing clinical workflows without structural disruption was cited as particularly valuable.

In practical terms, Switzerland can function both as a launch environment and as a reference market. Adoption within respected Swiss institutions can support broader European rollout strategies.

Stability as a competitive advantage

In an industry defined by long development cycles, predictability matters.

Executives highlighted Switzerland’s political and regulatory stability as a strategic asset. Tax frameworks and policy environments are perceived as consistent over time, enabling companies to plan reinvestment and growth with greater confidence.

At both macro and micro levels, stability reduces uncertainty. Companies can negotiate long-term frameworks and operate within a predictable decision-making environment, conditions that are particularly relevant when scaling capital-intensive life sciences operations.

This business-friendly orientation, combined with structural reliability, differentiates Switzerland within a European context often characterized by policy shifts and fragmentation.

Switzerland as a gateway, not just a market

Beyond its domestic advantages, Switzerland is frequently viewed as a gateway.

Although not a member of the European Union, Switzerland offers access to European markets while maintaining a regulatory and operational environment that is efficient and internationally oriented. This relationship was further reinforced in March 2026, when Switzerland and the EU signed a comprehensive bilateral agreement package strengthening cooperation in health, research programs, and market-related areas, providing greater legal clarity and deeper integration with European frameworks relevant to innovative sectors. For U.S. companies, establishing operations in Switzerland can facilitate broader European engagement while benefiting from a concentrated ecosystem.

Executives also noted cultural alignment between Switzerland and leading U.S. innovation hubs. Entrepreneurial mindset, efficiency in business formation, and openness to international collaboration create operational familiarity.

In this sense, Switzerland is not merely a destination market but a platform for expansion.

Ecosystem thinking over isolated incentives

A notable takeaway from the discussions was that companies do not evaluate single incentives in isolation. They evaluate ecosystems.

Capital without talent is insufficient. Talent without clinical validation pathways is limiting. Stability without growth potential does not attract expansion.

Switzerland’s strength lies in the combination:

• Government-supported early innovation
• Concentrated talent in health sciences
• Advanced clinical institutions
• Stable regulatory and fiscal frameworks
• International orientation

Together, these elements create an environment where companies can move from research to validation to commercialization with reduced friction.

The role of ecosystem connectors

International expansion is rarely executed without local guidance.

During its meetings in California, GGBa emphasized its role in facilitating connections between U.S. companies and relevant Swiss stakeholders. This includes introducing companies to cantonal authorities, research institutions, and industrial partners aligned with their strategic needs.

Rather than positioning Switzerland through marketing claims, the discussions focused on practical pathways: where to locate operations, how to navigate funding programs, how to identify hospital partners, and how to structure long-term growth.

For companies considering European expansion, such ecosystem-level facilitation can accelerate decision-making and reduce entry barriers.

A strategic European base

The conversations in California did not suggest that Switzerland is the only option for life sciences expansion. Rather, they highlighted why it is frequently considered one of the most efficient and strategically coherent ones.

In a global life sciences environment characterized by rising competition, technological acceleration, and regulatory complexity, companies increasingly prioritize ecosystems that combine funding continuity, talent density, clinical credibility, and operational stability.

Switzerland’s ability to integrate these factors positions it as a strong candidate for companies seeking to scale internationally.